PD-1 and PD-L1 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

PD-1 & PD-L1 Inhibitors Market Analysis

The PD-1 and PD-L1 inhibitors market is expected to register a CAGR of 16.8% over the forecast period.

The outbreak of the pandemic had a significant impact on cancer treatment across the globe. For instance, as per the study titled, "Effect of the COVID-19 pandemic on cancer treatment and research" published in June 2020, the influx of large numbers of COVID-19 patients requiring intensive monitoring and mechanical ventilation has overwhelmed hospital systems in affected regions and countries, disrupting the routine treatment of hematology and oncology patients, who constitute a particularly fragile and vulnerable population, and whose outcomes are likely to be negatively affected if the usual standard of care is delayed. It also stated that travel restrictions, patient concerns, regulatory guidelines, and oncology staff have resulted in many outpatient oncology patient visits being replaced by telephone consultations and postponing some routine therapies, tests, and procedures. Therefore, such instances indicate that the market witnessed an adverse impact on the market initially. However, in later times the positive developments helped the market to gain positive momentum, thereby propelling the market post pandemic.

The increasing cases of cancer across the globe are one of the major factors promoting the market growth over the forecast period. For instance, as per the report published by the World Health Organization in February 2022, cancer is one of the leading causes of death globally, accounting for nearly 10.0 million deaths in 2020, or nearly one in six deaths. It also reported that around 400,000 children develop cancer each year. Similarly, as per the report published by the American Cancer Society in January 2022, around 1,918,030 people is expected to suffer from cancer and around 609,360 people are expected to die from cancer in 2022 in the United States. A protein found on T cells (a type of immune cell) helps to keep the body's immune responses in manageable conditions. When PD-1 binds to another protein called PD-L1, it helps to prevent T cells from killing other cells, including cancer cells. Therefore, increasing cases of cancer is anticipated to propel the demand of PD-1 and PD-L1 inhibitors, thereby surging the market growth over the forecast period.

However, the high risk of complications associated with the highly expensive oncology treatment and challenges in development with uncertainty in the regulatory process & high costs of clinical trials are likely to restrain the market growth over the forecast period.

PD-1 & PD-L1 Inhibitors Market Trends

This section covers the major market trends shaping the PD-1 & PD-L1 Inhibitors Market according to our research experts:

PD-1 Inhibitors Segment is Expected to Witness Growth Over the Forecast Period

PD-1 & PD-L1 Inhibitors Industry Segmentation

Programmed cell death protein 1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are a group of new checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. These immune checkpoint inhibitors are also active in pregnancy following tissue allografts and emerging as a front-line treatment in immunotherapy for several types of cancer. An indication of specific staining interpretation defines tumor PD-L1 status. The PD-1 and PD-L1 inhibitors market is segmented by Inhibitors (PD-1 Inhibitors and PD-L1 Inhibitors), Application (Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, and Other Applications), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.